Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD101 topical is the first and only agent of its class being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.


Download Documentation Corporate Presentation October 2016

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$10.08 + 0.151.51%150,585
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
10/21/16 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $10.08 with a 52 week high of $18.07 and a 52 week low of $9.41.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources